Shares of Dianthus Therapeutics (NASDAQ:DNTH) jumped 5.8% after William Blair initiated coverage on the stock with an Outperform rating, marking the 13th buy recommendation the clinical-stage biotech has received.
Analyst Mylers Minter led the coverage, assigning a fair value of $47.57 per share, highlighting the company’s potential in the autoimmune space. Dianthus is currently developing DNTH103, an active C1s monoclonal antibody aimed at treating autoimmune neuromuscular disorders.
“We are initiating coverage of Dianthus Therapeutics with an Outperform rating and fair value of $47.57 per share. Dianthus is a clinical-stage biotech company developing DNTH103, an active C1s monoclonal antibody, for autoimmune neuromuscular indications. Risks to an investment are primarily clinical, regulatory, and commercial in nature, similar to other biotechnology companies,” Minter noted in the initiation report.
The positive outlook from William Blair reinforces strong sentiment surrounding the company, which now holds 13 buy ratings and no hold or sell recommendations from Wall Street analysts. The wave of bullish coverage reflects growing confidence in Dianthus’ lead candidate and its progress toward addressing unmet needs in neuromuscular disease treatment.